Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β,and Galectin-3 expression and improving systolic–diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial was conducted at three hospitals in East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, and Dr. Iskak Hospital Tulungagung, between 1 June and 31 December 2023. A total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day 1 and day 5 by ELISA, while NT-proBNP was tested on days 5 and 30. Transthoracic echocardiography was also performed on day 5 and day 30. Results: By day 30, no significant improvements in systolic–diastolic echocardiography parameters had been shown in the colchicine group. However, colchicine reduced the level of NT-proBNP on day 30 more than placebo (ΔNT-proBNP: −73.74 ± 87.53 vs. −75.75 ± 12.44 pg/mL; p < 0.001). Moreover, colchicine lowered the level of Caspase-1 expression on day 5 and the levels of TGF-β and Galectin-3 expression on day 1. Conclusions: Colchicine can reduce NT-proBNP, Caspase-1, TGF-β, and Galectin-3 expression significantly among AMI patients. Colchicine administration was capable of reducing post-AMI inflammation, ventricular dysfunction, and heart failure but did not improve systolic–diastolic echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of myocardial infarction (MI) remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation and Interleukin-1β (IL-1β) expression in fibroblasts. 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 h to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 h. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post hoc tests. Hypoxia treatment significantly induced apoptosis-associated speck-like protein containing a CARD (ASC)-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
Background : Caspase-1 (reflects NOD-like receptor protein 3 inflammasomes activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant role in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI, however, its direct benefit remains controversial. Objectives . This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression and improving echocardiography parameter among AMI patients. Methods. Double‐blinded, placebo‐controlled, randomized, multicenter clinical trial was conducted at 3 hospitals in East Java Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, Dr. Iskak Hospital Tulungagung between 1 June-31 December 2023. Total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day-1 and day-5 by ELISA, whilst NT-proBNP were tested on day 5 and 30. Transthoracic echocardiography were also tested on day 5 and day 30. Results. On day-30, no significant improvement in echocardiography parameter had been shown in colchicine group. However, colchicine reduces level of NT-proBNP on day-30 greater than placebo (ΔNT-proBNP: -273.74 ± 87.53 vs. -75.75 ± 12.44 pg/mL; p<0.001). Moreover, colchicine lower level of Caspase-1 expression on day-5, level of TGF-β and Galectin-3 expression on day-1. Conclusion. Colchicine can reduce NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression significantly among AMI patients but didn’t improve echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of MI remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NLRP3 inflammasome activation and IL-1β expression in fibroblasts. The 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 hours to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 hours. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post-hoc tests. Hypoxia treatment significantly induced ASC-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.